Please select the option that best describes you:
Would you choose a different anti-CD20 antibody in early relapsed (< 6 months) DLBCL treated with rituximab?
Is there a preference for obinutuzumab over rituximab in early relapsed DLBCL, or in primary refractory disease?
Answer from: Medical Oncologist at Academic Institution
Unfortunately, the largest clinical trial asking the same question you pose here—does substitution of the anti-CD20 antibody in combination with platinum-based chemotherapy in relapsed/refractory DLBCL following RCHOP improve outcomes—has failed to demonstrate benefit to such an approach...
Sign in or Register to read more